NL8601979A - Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. - Google Patents

Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. Download PDF

Info

Publication number
NL8601979A
NL8601979A NL8601979A NL8601979A NL8601979A NL 8601979 A NL8601979 A NL 8601979A NL 8601979 A NL8601979 A NL 8601979A NL 8601979 A NL8601979 A NL 8601979A NL 8601979 A NL8601979 A NL 8601979A
Authority
NL
Netherlands
Prior art keywords
coenzyme
pharmaceutical preparations
creatine phosphate
preparations according
muscle
Prior art date
Application number
NL8601979A
Other languages
English (en)
Dutch (nl)
Original Assignee
Seuref Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seuref Ag filed Critical Seuref Ag
Publication of NL8601979A publication Critical patent/NL8601979A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL8601979A 1985-08-06 1986-08-01 Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. NL8601979A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3362/85A CH666183A5 (it) 1985-08-06 1985-08-06 Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
CH336285 1985-08-06

Publications (1)

Publication Number Publication Date
NL8601979A true NL8601979A (nl) 1987-03-02

Family

ID=4254335

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8601979A NL8601979A (nl) 1985-08-06 1986-08-01 Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme.

Country Status (8)

Country Link
JP (1) JPS6253924A (ja)
BE (1) BE905210A (ja)
CH (1) CH666183A5 (ja)
DE (1) DE3625433A1 (ja)
FR (1) FR2586352B1 (ja)
GB (1) GB2178661B (ja)
IT (1) IT1213319B (ja)
NL (1) NL8601979A (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19537494C2 (de) * 1995-09-25 1997-10-02 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
DE202023001978U1 (de) 2023-09-20 2023-09-29 Penta Phi Eg Formulierung umfassend Coenzym Q10 und Kreatin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Also Published As

Publication number Publication date
BE905210A (nl) 1986-12-01
GB2178661B (en) 1989-08-31
CH666183A5 (it) 1988-07-15
FR2586352B1 (fr) 1992-05-29
FR2586352A1 (fr) 1987-02-27
IT8621394A0 (it) 1986-08-01
GB8618589D0 (en) 1986-09-10
JPS6354690B2 (ja) 1988-10-28
DE3625433A1 (de) 1987-02-19
GB2178661A (en) 1987-02-18
IT1213319B (it) 1989-12-20
JPS6253924A (ja) 1987-03-09

Similar Documents

Publication Publication Date Title
Wade et al. Antioxidant characteristics of L-histidine
Bravenboer et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat
DE3855120T2 (de) The use of AICA riboside or AICA ribotide for the preparation of a medicament against heart attack or stroke in patients with atherosclerosis
Endo et al. Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms.
ES2262741T3 (es) Uso de acidos grasos poliinsaturados para la prevencion de accidentes cardiovasculares importantes.
JPH0649651B2 (ja) 心筋虚血治療用医薬組成物
JPH1087483A (ja) 神経系および心循環系に対する酸化ストレスにより惹起する疾患の予防および治療のためのｌ−カルニチンまたはその誘導体と抗酸化剤の使用
EP0786993B1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders
JP2002523456A (ja) アスコルビン酸塩−イソケルセチン組成物
Aronow et al. Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure
NL8601979A (nl) Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme.
US5631234A (en) Method for treating ischemia-reperfusion tissue injury
US4451485A (en) Treatment of cardio-vascular diseases with 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
Demoulin et al. Prognostic significance of electrocardiographic findings in angina at rest. Therapeutic implications.
Beedkar et al. Heart failure and the iron deficiency
Tripathi et al. Effect of�-Tocopherol Pretreatment on Infarct Size following 90 Minutes of Ischemia and 4 Hours of Reperfusion in Dogs
EP0406327B1 (en) Long lasting composition of propafenone and quinidine for treatment of cardiac conditions
CA2083609C (en) Preventive or therapeutic agent for ischemia-reperfusion tissue injury, arrhythmia and lung injury caused by active oxygens and free radicals
Levett et al. Effects of dimethyl sulfoxide on systemic and cerebral hemodynamic variables in the ischemic canine myocardium
HU228959B1 (en) Use of specific dose of fondaparinux sodium for preparation of medicament for treatment of acs
JPH0561251B2 (ja)
EA003470B1 (ru) Фармацевтическая композиция тгп и ингибитора апф
WO2023218364A1 (en) Anti-aging and anti-inflammatory compositions comprising nicotinamide mononucleotide and reservatrol and uses thereof
JPH0526766B2 (ja)

Legal Events

Date Code Title Description
BV The patent application has lapsed